Skip to main content
. 2016 Jul 6;7(29):44950–44965. doi: 10.18632/oncotarget.10440

Figure 3. AagTg mice treated with a Parp inhibitor exhibit MMS-mediated renal toxicity similar to AagTg/Parp1−/− mice.

Figure 3

H&E stained images of kidneys from WT, AagTg, and AagTg/Parp1−/− mice 20 days (A) and 30 days (B) following MMS (75 mg/kg) and/or ABT-888 (10 mg/kg) treatment as indicated. ABT-888 was administered 1 hour prior and 5 days post-MMS treatment. Magnification is 100X, 200X (scale bar 50 μm) and 600x (scale bar 10 μm); MMS- and ABT-888-treated AagTg mice show islands of pink proteinaceous casts, dilation of the kidney tubules, and few glomeruli with severe abnormalities (including vacuolation and the loss of Bowman's space) as seen in AagTg/Parp1−/− mice post-MMS treatment.